Get My Favorite Coffee and Espresso System for Free With This Deal Right Now
The main reason for this change is the L'Or Barista coffee and espresso system, which is currently free when you order $79 worth of coffee capsules.
L'Or is running several other promotions on its coffee and systems, such as 15% capsule orders, so take advantage before these deals disappear soon. Plus, you can grab the L'Or system and frother bundle for 59% off.
I bought my mom this system for Christmas and we've both become L'Or evangelists. With this deal, it's not a bad time to gift your caffeine-loving parents, friends or loved ones (or yourself -- I won't judge) my all-time favorite coffee and espresso system.
Hey, did you know? CNET Deals texts are free, easy and save you money.
Why I love my L'Or Barista
The Pumpkin Spice capsules are my go-to in the fall, but the iced coffee capsules are my favorite during the summer months.
Macy Meyer/CNET
Every morning, I wake up giddy to make my coffee. The Onyx Espresso capsules are my consistent go-to when I make my favorite salted maple iced lattes, which are perfect for warm, summer mornings, but I'm also a huge fan of the iced coffee capsules. Since I've perfected my morning caffeine routine with the L'Or Barista, I no longer feel any need to buy coffee out. In fact, I prefer making my coffee and espresso drinks at home since I can use my machine to tailor them to my mood on that given morning.
I also love how quickly the machine heats up -- a flat 25 seconds to be exact. Nothing feels worse than waiting and waiting for a coffee machine to turn on, heat up and brew up a batch of java. Mere minutes can feel like an eternity when I'm exhausted and desperate for the energy that first cup of caffeine brings me.
What comes with the system?
The L'Or Barista is a single-serve machine that uses high-pressure brewing to make both coffee and espresso beverages at home. The system can brew six different sizes of hot or iced coffee, as well as espresso.
The sleek machine, which is compact enough to fit on a kitchen counter, is a highlight, but the capsules are also an exciting treat. Since you'll need to spend $79 or more for a free system, you can opt to taste a variety of capsule flavors. I've tried the caramel, hazelnut and Le Tigre coffee capsules and numerous espresso options -- it's genuinely hard to pick a favorite.
Best Prime Day Kitchen Appliance Deals
Score some of the best discounts of the year on top kitchen tech during Prime Day, and our shopping experts have rounded up the only deals worth taking seriously this year.
See Now
Why this makes a great gift
At its discounted price tag (usually $199), the L'Or Barista would be a great gift for any coffee connoisseur in your life. In fact, my mom tried mine, became obsessed, and would subtly bring it up until I finally bought her one for Christmas. The current sale would provide the perfect opportunity to get some key birthday or back-to-school shopping done (wink, wink).
Basically, this system comes with everything you need for a complete at home barista experience, while taking any hassle out of the process.
For more tips to feel like a master barista, explore our roundup of the best espresso machines. You should also read how to make great lattes at home on the cheap.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
a minute ago
- Associated Press
NFL Players Association executive JC Tretter is resigning amid union overhaul
WASHINGTON (AP) — NFLPA chief strategy officer JC Tretter is resigning from his position, three days after Lloyd Howell stepped down as executive director of the players' union. Tretter told CBS Sports on Sunday that he doesn't want to be considered for the NFLPA's interim executive director position and denied he played any role in undermining Howell's position. 'Over the last couple days, it has gotten very, very hard for my family. And that's something I can't deal with,' Tretter told CBS Sports on Sunday. 'So, the short bullet points are: I have no interest in being (executive director). I have no interest in being considered. I've let the executive committee know that. I'm also going to leave the NFLPA in the coming days because I don't have anything left to give the organization.' The 34-year-old Tretter, who played center for eight seasons with Green Bay and Cleveland through 2021, was the player president from 2020 to 2024. He served in his new role since October 2024. Howell resigned Thursday after two years because his leadership had become a distraction. Howell has come under scrutiny since ESPN reported he has maintained a part-time consulting job with the Carlyle Group, a private equity firm that holds league approval to seek minority ownership in NFL franchises. That followed the revelation that the NFLPA and the league had a confidentiality agreement to keep quiet an arbitrator's ruling about possible collusion by owners over quarterback salaries. The latest issue was an ESPN report Thursday that revealed two player representatives who voted for Howell were not aware that he was sued in 2011 for sexual discrimination and retaliation while he was a senior executive at Booz Allen. In 2023, a year after the NFLPA sued the owners for collusion, the NFL sued the union after Tretter suggested in an interview that running backs who were unhappy with their contracts could fake injuries, which would be a violation of the collective bargaining agreement. The grievance also was decided this year and was not shared publicly. Tretter told CBS Sports he didn't have access to the collusion grievance and wasn't involved in the confidentiality agreements. Tretter was the NFLPA's player president in 2023 when Howell was elected as the union's executive director following a vote that changed the union's constitution and made the search and election process more confidential. 'I'm not resigning because what I've been accused of is true,' Tretter said. 'I'm not resigning in disgrace. I'm resigning because this has gone too far for me and my family, and I've sucked it up for six weeks. And I felt like I've been kind of left in the wind taking shots for the best of the organization. ... And in the end, what's the organization done for me? Like, nothing.' ___ AP NFL:
Yahoo
29 minutes ago
- Yahoo
A Once-in-a-Lifetime Opportunity: This Blue Chip Healthcare Stock Down 50% Could Double Your Money
Key Points Novo Nordisk's recent financial results and clinical progress haven't impressed Wall Street. However, the company can right the ship through innovation in its core specialty and elsewhere. The stock looks attractively valued at current levels and could beat the market over the next six years. 10 stocks we like better than Novo Nordisk › Investors looking to strike while the iron is hot can buy beaten-down stocks that appear to have excellent chances of bouncing back. And that describes shares of Novo Nordisk (NYSE: NVO) very well. The pharmaceutical leader is down by 52% over the trailing-12-month period as of July 17, but initiating a position now could double investors' money in six years or so. Here's why this stock is a screaming buy at its current levels. Novo Nordisk's recent challenges Novo Nordisk focuses on developing diabetes treatments, an area where it has been a leader for many decades. As of February, it held a 33.3% market share for diabetes drugs. This sort of long-term dominance doesn't happen by accident. The company has consistently attracted top talent in the pharmaceutical industry, which, combined with its extensive experience in diabetes, has enabled it to break new ground repeatedly. Why, then, have the company's shares dropped by 52% over the past year? Because Novo Nordisk failed to impress the market with its financial results and clinical progress. The developments that led to the drugmaker's share plunge would have been excellent for almost any other pharmaceutical company, but investors held it to a higher standard given its rich valuation metrics. For instance, the company reported phase 3 results for CagriSema, an investigational weight management medicine, that proved it's more effective than its famous semaglutide (Wegovy), reducing patients' weight by an average of 22.7% in 68 weeks. However, management was looking for a 25% figure in the study. Very few anti-obesity therapies in development have achieved results comparable to CagriSema, but that was not enough to please investors. The good news: Novo Nordisk's pipeline in diabetes and the fast-growing area of weight management remains robust. The company has several promising candidates in development, including Amycretin, for which it recently initiated late-stage studies. And management has significantly expanded its pipeline through acquisitions. Even with mounting competition, the company should continue to be one of the leaders in its core areas of focus. It's been developing medicines in other fields as well, including various rare diseases (such as the blood disorders beta thalassemia and sickle cell disease), neurological disorders (including Alzheimer's and Parkinson's), and others. Making progress in diabetes and obesity while diversifying its lineup should work wonders for Novo Nordisk down the line. The price is right Net sales in the first quarter grew by 19% year over year to 78.1 billion Danish krone ($12.1 billion). The company's net profit was up 14% year over year to $4.5 billion. These would be excellent results for most similarly sized drugmakers, yet Wall Street remains unimpressed. In my view, that has created a wonderful opportunity to buy shares on the dip. The company's forward price-to-earnings ratio (P/E) has declined significantly over the past year and now stands at 16.9, barely above the healthcare industry's 16.2 and lower than the S&P 500's 22.3. But given Novo Nordisk's still excellent position in its core markets of diabetes and obesity treatments -- the latter of which should grow rapidly in the coming years -- and the company's better-than-average revenue and earnings growth, its stock is arguably worth a steeper premium. In fact, the forward P/E is about as low as it has been in over two years. At current levels, shares look like a steal. Here is how things could evolve for the company in the next six years. First, it could make significant clinical and regulatory progress and launch at least one -- if not several -- blockbuster weight loss or diabetes medications. Second, the company should continue recording strong results, with revenue and earnings moving in the right direction. Lastly, it looks likely to continue increasing its dividend, which it has done significantly over the past half-decade. The stock needs a compound annual growth rate of 12.2% to double in the next six years. Novo Nordisk can pull it off, especially for those who opt to reinvest the dividend. Should you buy stock in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025 Prosper Junior Bakiny has positions in Novo Nordisk. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. A Once-in-a-Lifetime Opportunity: This Blue Chip Healthcare Stock Down 50% Could Double Your Money was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29 minutes ago
- Yahoo
You Have $1,000 to Invest. Should You Buy GOOG or GOOGL?
Key Points Alphabet offers investors exposure to powerful tech megatrends like artificial intelligence (AI), cybersecurity, and autonomous transportation -- all under one roof. Alphabet trades under two ticker symbols, but they both represent the same underlying business. Unless voting rights are important to you, either ticker is a great way to invest in this "Magnificent Seven" stock. 10 stocks we like better than Alphabet › The "Magnificent Seven" is a popular tag for the most dominant, high-performing tech companies on the planet. Alphabet (NASDAQ: GOOGL), (NASDAQ: GOOG), Amazon, Apple, Meta Platforms, Microsoft, Nvidia, and Tesla have delivered market-crushing returns over the past decade, in large part because their businesses are on the forefront of the most disruptive technology macrotrends in modern history. While all seven companies are juggernauts in their own right, one Magnificent Seven stock stands out due to its dominant core business, exposure to multiple megatrends, and attractive valuation relative to its cohorts. That stock is Alphabet. An unconventional company There's something else that makes Alphabet different. Unlike the other members of the Magnificent Seven, Alphabet trades under two tickers: GOOG and GOOGL. Why would Alphabet do that? A little history will provide some helpful context. Larry Page and Sergey Brin founded Google (Alphabet's predecessor) in 1998. When Google filed its IPO paperwork in 2004, Page declared in a letter to prospective shareholders: "Google is not a conventional company. We do not intend to become one." In that same letter, Page fretted that becoming a public company could undermine the independence and creative spirit that had been critical to Google's success. He also made it clear that the company would not "shy away from high-risk, high-reward projects" just to hit some arbitrary quarterly financial target. To ensure that Page, Brin, and the rest of the executive team would retain "control over the company's decisions and fate," Google implemented a dual-class stock structure. It's all about insider control Common stock represents partial ownership in a company, and it usually comes with the right to vote on issues such as executive compensation, board members, and mergers and acquisitions. When Google debuted as a publicly traded company in August 2004, it used the dual class structure to concentrate 99% of the voting power in the hands of its founders, executives, and board members. Here's how: Each share of Class A common stock (available to regular investors) came with one vote. Each share of Class B common stock (held by founders and insiders) came with 10 votes. At the time, Page acknowledged that this was an unconventional move for a tech company, although it wasn't uncommon for other types of businesses. Perhaps the most well-known example is Berkshire Hathaway. However, in the years since Google's 2004 IPO, a number of tech companies have adopted dual class structures to maintain insider control, including Meta Platforms, Palantir, and Roblox. . This is where it gets a little confusing In April 2014, Google added another layer of complexity to its share structure by way of a 2-for-1 stock split. On April 2, 2014, Google's shareholders received one share of newly issued Class C stock for every share of Class A stock that they already owned. Starting on April 3, 2014, two classes of Google stock were available to the public: Class A shares (GOOGL): One vote per share Class C shares (GOOG): No voting power The important thing to note is the Class C shares don't come with voting rights. That was the whole point of the 2014 stock split. By issuing nonvoting Class C shares, Google could fund acquisitions and offer stock-based compensation and incentives without diluting executives' voting power. To recap, this is the share structure that exists today: Class A shares (GOOGL): One vote per share Class B shares (held by insiders): 10 votes per share Class C shares (GOOG): No voting power Should you buy GOOG or GOOGL? Today, Google the search engine is just one piece of Alphabet, the umbrella company formed in 2015. What makes Alphabet such a compelling investment is that it's not just a search-engine provider. Owning Alphabet is a bit like owning an ETF with exposure to some of the biggest themes in tech -- from cloud computing and AI to autonomous vehicles, cybersecurity, and streaming. And as I alluded to earlier, Alphabet trades at a discount to its Magnificent Seven cohorts based on its forward price-to-earnings (P/E) ratio: But there's still one question left to answer: Is GOOG or GOOGL the better investment? Because GOOGL comes with voting rights, you'd think it would trade at a premium to its Class C sibling, GOOG. But interestingly enough, GOOG has outperformed GOOGL since April 3, 2014, ever-so-slightly: As of July 16, GOOG was priced at $183.77, just a hair above GOOGL at $182.97. So based on the recent price action, you could look at it this way: GOOGL gives you the same exposure to Alphabet's basket of businesses, but at a slightly lower price, with the added benefit of voting power. In reality, most regular investors can't purchase enough shares to have any meaningful impact on the company's strategic direction through their votes. And because both tickers represent the same underlying security, there likely will never be any wide variation in price between the two. So unless you care deeply about voting rights, either ticker is a great way to invest in this Magnificent Seven standout. Should you buy stock in Alphabet right now? Before you buy stock in Alphabet, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Alphabet wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. Josh Cable has positions in Alphabet, Amazon, Berkshire Hathaway, Microsoft, Nvidia, and Palantir Technologies. The Motley Fool has positions in and recommends Alphabet, Amazon, Apple, Berkshire Hathaway, Meta Platforms, Microsoft, Nvidia, Palantir Technologies, Roblox, and Tesla. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. You Have $1,000 to Invest. Should You Buy GOOG or GOOGL? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
